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Abstract
Objectives The aim was to define sub-optimal response to TNF inhibitors (TNFi), compare long-term
drug survival rates and identify predictors of sub-optimal response in axial spondyloarthritis (axSpA)
patients in a UK cohort.
Methods All axSpA patients attending two centres who commenced TNFi between 2002 and 2016 were
included. Routinely recorded patient data were reviewed retrospectively. Patients with paired BASDAI at
baseline, 3 and/or 6 months were included for analysis. Sub-optimal response was defined as achieving
a 2-point reduction in BASDAI but not BASDAI50, post-treatment BASDAI remaining at 4, and in the
opinion of the treating physician these patients demonstrated a meaningful clinical response.
Results Four hundred and ninety-nine patients were included: 82 (16.4%) patients were classified as
having a sub-optimal response; 64 (78%) males, 78 (95.1%) AS and 55/67 (82.1%) HLA-B27 positive.
Results are reported as the mean (S.D.). Time to diagnosis was 10 (8.6) years, age at diagnosis was 37
(11.7) years, and age at initiating index TNFi was 48 (11.1) years. Individual index TNFi were Humira (adali-
mumab, n¼ 41, 50%), Enbrel (etanercept, n¼ 27, 32.9%), Remicade (infliximab, n¼ 5, 6.1%), Simponi
(golimumab, n¼ 3, 3.7%) and Cimzia (certolizumab pegol, n¼ 6, 7.3%). The rate of attrition was greater
among sub-optimal responders at 2 and 5 years (P< 0.05), but not at 10 years (P¼ 0.06), compared with
responders. Older age at initiation of TNFi was a predictor of sub-optimal response (odds ratio 1.04, 95%
CI 1.01, 1.09, P< 0.05).
Conclusion A significant proportion of patients continued TNFi despite demonstrated sub-optimal re-
sponse. Further research needs to be undertaken in order to understand this group.
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Introduction
The use of TNF inhibitors (TNFi) has been proved to be
an effective treatment for most patients with axial spon-
dyloarthritis (axSpA). Patients treated with TNFi have
reported efficacy, with significant improvements in pain,
disease activity and physical function [1–5]. Serological
and imaging parameters also show demonstrable
improvements after treatment. Predictors of positive re-
sponse to TNFi include HLA-B27 positivity, younger age
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at treatment initiation, widespread inflammation on MRI
at baseline and elevated CRP levels [6–8].
Despite the successes of TNFi in treating axSpA,
some patients fail to demonstrate a good response to
TNFi. The rates of switching first TNFi owing to lack of
or loss of efficacy range from 14 to 56% [9]. Older age,
negative HLA-B27 and higher baseline BASDAI were
reported as predictors of primary inefficacy of TNFi [10].
Although not universally effective for all patients, TNFi
use may provide a degree of benefit for patients, which
could subsequently influence the decision to continue
treatment.
As the use and experience of using TNFi in axSpA
increases, it is apparent that a second group of TNFi
responders exist. These are patients who respond to
TNFi, but the response is sub-optimal. The aim of this
study was to define sub-optimal response to TNFi in
axSpA, compare long-term drug survival rates and as-
sess predictors in this group of patients.
Methods
Patients
A retrospective analysis of axSpA patients (n¼499) who
commenced TNFi at two specialist centres (The Royal
National Hospital for Rheumatic Diseases, Bath and the
Norwich and Norfolk University Hospital National Health
Service Foundation Trust, UK) between 2002 and 2016
was undertaken, and patients with paired BASDAI [11]
at baseline and at 3 and/or 6 months post-treatment
were included. TNFi survival data from this cohort have
recently been published [12]. All patients had a
physician-verified diagnosis of axSpA and were eligible
for biologics according to the National Institute for
Health and Care Excellence (NICE) criteria (TA383) [13].
There is no formal requirement for clinical databases to
apply for ethical review under National Health Service
research governance systems, and therefore analysis of
anonymized data did not require ethical approval.
Demographic data, including age, sex, date of symp-
tom onset, age at diagnosis, age at TNFi initiation, smok-
ing history, family history of SpA and HLA-B27 status,
were recorded. Extra-articular manifestations, including
acute anterior uveitis, psoriasis and IBD, baseline
BASDAI and individual TNFi drugs, were also recorded.
The first initiated TNFi was defined as the index drug.
Standard practice in both centres is not to adjust other
pharmacological therapies within the first 6 months of ini-
tiating TNFi.
Disease activity and treatment response
BASDAI was assessed at baseline, 3 and/or 6 months af-
ter TNFi initiation. AS disease activity score [14] was not
routinely calculated, because CRP had not been a pre-
requisite for TNFi initiation under existing NICE guidelines
[13].
We defined sub-optimal response as patients who
achieved at least a two ( 2)-point reduction at either 3
and/or 6 months from baseline but did not achieve
BASDAI50, and BASDAI remained at  4 at 6 months,
and in the opinion of the treating physician these
patients demonstrated a meaningful clinical response.
However, it is important to note that despite demon-
strating a clinical response, the decision to continue
TNFi therapy was based on a shared decision between
the patient and the physician. The primary outcome was
patients achieving sub-optimal response at 3–6 months.
All patients who continued on index TNFi treatment after
6 months were identified and included in the survival
analysis.
Predictors of sub-optimal response to TNFi were ana-
lysed. Patients’ age, sex, time to diagnosis (symptom
onset to date of diagnosis), age at diagnosis, age at
TNFi initiation, smoking history, family history, HLA-B27
status, presence of extra-articular manifestations, choice
of individual TNFi drug, baseline BASDAI and its sub-
components were included as variables. Detailed
records of concomitant NSAIDs use were not available.
Statistical analysis
Statistical analysis was undertaken using SPSS Statistics
v.22.0 (IBM Corp., Armonk, NY, USA). Predictors of sub-
optimal response to treatment were identified. Non-
parametric testing, including Mann–Whitney and v2, were
used to compare between groups, whereas the Wilcoxon
signed-rank test was used for comparison within the
group. Survival probabilities were estimated using the
Kaplan–Meier method and compared using the log-rank
test. Logistic regression analysis was used to assess pre-
dictors of sub-optimal response. Multivariable models
were used when adjusted for sex, time to diagnosis, age
at diagnosis, age at TNFi initiation, smoking history, fam-
ily history, presence of extra-articular manifestations
(acute anterior uveitis, psoriasis and IBD), HLA-B27 sta-
tus, choice of individual TNFi drug and baseline BASDAI
sub-components. Baseline total BASDAI was excluded
from the final model because it has a high collinearity
with the individual sub-components of BASDAI. A P-value
of <0.05 was considered statistically significant.
Results
Four hundred and ninety-nine axSpA patients (AS
n¼467, 93.6%) who commenced TNFi, and for whom
paired BASDAI at baseline and at either 3 and/or
6 months were available, were recruited.
Results are reported as the mean (S.D.). The number
of patients who were classified as having sub-optimal
response ( 2-point reduction without achieving
BASDAI50 but BASDAI remained  4 at 6 months) was
82/499 (16.4%). These sub-optimal responders con-
sisted of 64 males (78%), 78 (95.1%) diagnosed with
AS, and 55/67 (82.1%) were HLA-B27 positive. Time to
diagnosis was 10 (8.6) years, age at diagnosis was 37
(11.7) years, and age at starting index TNFi was 48
(11.1) years. Extra-articular manifestations included
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acute anterior uveitis (17/67, 25.4%), psoriasis (14/68,
20.6%) and IBD (7/65, 10.8%). Family history was posi-
tive in 12/40 (30%) patients, and 17/70 (24.3%) were ac-
tive smokers.
The sub-optimal responders were treated for a total of
355 patient-years. Index TNFi used were Humira (adali-
mumab, n¼41, 50%), Enbrel (etanercept, n¼27,
32.9%), Remicade (infliximab, n¼ 5, 6.1%), Simponi
(golimumab, n¼3, 3.7%) and Cimzia (certolizumab
pegol, n¼6, 7.3%). At 6 months and 1 year, the survival
rates among sub-optimal responders who remained on
index TNFi treatment were 90.2 and 85.1%, respec-
tively. The rate of attrition was greater among sub-
optimal responders at 2 years (75.5 vs 91%, log rank
P<0.001) and 5 years (68.4 vs 79.9%, log rank
P<0.05), but at 10 years there was no difference be-
tween the sub-optimal responders and responders (68.4
vs 67.6%, log rank P¼0.064) (Fig. 1). Seventy per cent
(58/82) continued index TNFi, despite sub-optimal re-
sponse, throughout the entire course of follow-up.
Univariate and multivariate analyses of sub-optimal in-
dex TNFi response at 6 months are summarized in
Table 1. Older age at initiating TNFi was the best predic-
tor of sub-optimal response (P<0.05).
Discussion
This is the first study to define sub-optimal response
and describe the characteristics of sub-optimal TNFi
responders in axSpA. From a cohort of 499 axSpA
patients on TNFi, we have identified 82 (16.4%) patients
who achieved a sub-optimal response. Older age at initi-
ation of TNFi predicted this response. Approximately
90% of these sub-optimal responders continued on in-
dex TNFi treatment after 6 months.
To our knowledge, there is currently no consensus on
the definition of sub-optimal response to TNFi in axSpA.
The BASDAI is used widely in clinical practice in the UK
to define active disease and as a threshold for eligibility.
A cut-off value of 4 has been validated [15–17], and this
has been adapted by NICE as a threshold to initiate
TNFi treatment [13]. The NICE BASDAI criteria for con-
tinuing TNFi have also led to a group of patients being
able to continue their treatment despite a sub-optimal
response. This is further supported by the published bi-
ologic guideline from the British Society of
Rheumatology and the British Health Professionals in
Rheumatology [18].
In our study, >90% of patients with a sub-optimal re-
sponse continued on the index TNFi at 6 months. This
decision to continue TNFi treatment was at the discre-
tion of the treating physician, which implies that the
treating physician considered that they were responding
adequately; however, this might have been influenced
by switching limitations imposed by NICE guidelines at
that time. It is important to note, however, that the op-
tion for switching TNFi was available in both centres by
local agreement or via an individual funding request pro-
cess. Studies on continuing TNFi compared with switch-
ing in patients with a sub-optimal response are lacking.
We report older age at initiation of TNFi as a predictor
for sub-optimal response in axSpA. Younger age has
been previously reported as a positive predictor for TNFi
FIG. 1 Survival outcome according to response to index TNF inhibitor
TNF inhibitors in axial spondyloarthritis
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response [19, 20], whereas older age was reported as a
predictor of non-response [10]. There are a number of
reasons why older patients might be more susceptible
to a sub-optimal response. It is probable that greater
structural changes related to axSpA might be attribut-
able to longer disease duration. In addition, many older
patients will have concomitant degenerative spinal dis-
ease, the symptoms of which will not respond to TNFi
treatment. Finally, the presence of chronic pain syn-
dromes/secondary FM might also contribute to TNFi
sub-optimal response in older patients with a longer dis-
ease duration [21].
There are limitations to this study. This was a retro-
spective study based on two centres with limited follow-
up data and subjected to selection bias. Missing data
might also have contributed to selection bias, because
we did not carry out imputation methods during the sta-
tistical analyses. The BASDAI collected might not encap-
sulate the real decision to continue treatment. Data on
the presence of peripheral arthritis, enthesitis, CRP, sec-
ondary FM, degenerative spinal disease, NSAID use and
imaging data were not available for the present study
and might have influenced sub-optimal response. One in-
terpretation for continuing treatment in sub-optimal
responders is that BASDAI might not be capturing mean-
ingful clinical benefits as determined by patients and
physicians. This study also did not include data on all
currently available therapies. At the time of the study, IL-
17 inhibitors were not available; therefore, there was no
option to switch to another mode of action.
In summary, a significant proportion of patients con-
tinued TNFi despite demonstrating a sub-optimal re-
sponse. Older age at starting TNFi is a predictive factor.
Further studies are required to understand sub-optimal
response to TNFi from the perspective axSpA patients
and to investigate the optimal treatment choice for this
group of patients.
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TABLE 1 Univariate and multivariate regression analysis for predictors of index TNFi sub-optimal response at 6 months
Covariates Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
Sex, female 1.00 (0.56, 1.77) 0.995 – –
Diagnosis, AS 1.40 (0.48, 4.11) 0.537 – –
Time to diagnosis, duration (years) 1.00 (0.97, 1.03) 0.777 – –
Age at diagnosis (years) 1.04 (1.01, 1.06) 0.001* 1.01 (0.97, 1.04) 0.682
Age at TNFi initiation (years) 1.02 (0.99, 1.04) 0.060 1.04 (1.01, 1.09) 0.023*
HLA-B27, positive 1.19 (0.61, 2.34) 0.607 – –
Family history, present 1.02 (0.50, 2.05) 0.961 – –
AAU, present 0.61 (0.35, 1.09) 0.094 0.56 (0.24, 1.30) 0.179
Psoriasis, present 1.14 (0.59, 2.19) 0.689 – –
IBD, present 0.79 (0.34, 1.86) 0.598 – –
Smoking Never 1 – – –
Ex-smoker 1.03 (0.57, 1.84) 0.922 – –
Active 0.72 (0.38, 1.38) 0.329 – –
BASDAI baseline Total 1.92 (1.56, 2.35) <0.001* – –
Fatigue 1.39 (1.14, 1.72) 0.001* 1.06 (0.81, 1.38) 0.661
Spinal pain 1.41 (1.13, 1.75) 0.002* 0.98 (0.70, 1.37) 0.907
Joint pain 1.29 (1.13, 1.47) <0.001* 1.18 (0.97, 1.44) 0.086
Enthesitis 1.33 (1.14, 1.55) <0.001* 1.04 (0.84, 1.29) 0.726
Durationa 1.49 (1.21, 1.83) <0.001* 1.15 (0.82, 1.61) 0.414
Severitya 1.14 (1.01, 1.28) 0.026* 1.11 (0.94, 1.30) 0.213
Index TNFi drug Humira (ADA) 1 – – –
Enbrel (ETN) 1.19 (0.70, 2.03) 0.515 – –
Remicade (INFX) 1.04 (0.38, 2.88) 0.931 – –
Simponi (GOL) 0.52 (0.15, 1.80) 0.307 – –
Cimzia (CZP) 2.33 (0.85, 6.42) 0.101 – –
AAU: acute anterior uveitis; ADA: adalimumab; CZP: certolizumab pegol; ETN: etanercept; GOL: golimumab; INFX: inflixi-
mab; OR: odds ratio; TNFi: TNF inhibitor.
aRelated to morning stiffness.
*P-value is statistically significant.
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